PLRX vs. ETNB, IDYA, AUPH, CPRX, TVTX, LGND, BMEA, CRNX, CTIC, and MNKD
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include 89bio (ETNB), IDEAYA Biosciences (IDYA), Aurinia Pharmaceuticals (AUPH), Catalyst Pharmaceuticals (CPRX), Travere Therapeutics (TVTX), Ligand Pharmaceuticals (LGND), Biomea Fusion (BMEA), Crinetics Pharmaceuticals (CRNX), CTI BioPharma (CTIC), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Pliant Therapeutics vs.
Pliant Therapeutics (NASDAQ:PLRX) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.
In the previous week, 89bio had 7 more articles in the media than Pliant Therapeutics. MarketBeat recorded 9 mentions for 89bio and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.20 beat 89bio's score of 0.16 indicating that Pliant Therapeutics is being referred to more favorably in the media.
89bio has a net margin of 0.00% compared to Pliant Therapeutics' net margin of -1,359.22%. Pliant Therapeutics' return on equity of -39.05% beat 89bio's return on equity.
Pliant Therapeutics presently has a consensus target price of $47.83, indicating a potential upside of 110.07%. 89bio has a consensus target price of $34.00, indicating a potential upside of 68.57%. Given Pliant Therapeutics' higher probable upside, equities analysts clearly believe Pliant Therapeutics is more favorable than 89bio.
97.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 87.8% of 89bio shares are owned by institutional investors. 5.6% of Pliant Therapeutics shares are owned by insiders. Comparatively, 4.4% of 89bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Pliant Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, 89bio has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.
89bio has lower revenue, but higher earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.
89bio received 40 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 61.29% of users gave Pliant Therapeutics an outperform vote while only 60.94% of users gave 89bio an outperform vote.
Summary
Pliant Therapeutics beats 89bio on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
